Develop site-centric protocols to optimize enrollment and maximize performance
In an attempt to meet regulatory expectations, clinical trials are challenged by highly complex protocol design. But these study plans…
In an attempt to meet regulatory expectations, clinical trials are challenged by highly complex protocol design. But these study plans…
Regulatory investigators’ remit extends beyond routine standard operating procedure (SOP) reviews; they watch how operators work, how equipment is qualified,…
Biopharma licensing is becoming more operational. Buyers and partners still begin with the quality of the science, but they also…
The global map of clinical research is changing rapidly. Once viewed primarily as an attractive destination for cost-efficient clinical trials,…
The regulatory landscape across life sciences has faced unprecedented shifts over the past year. Simultaneous realignments of FDA, EU, and…
Ask any life sciences quality leader where their biggest compliance headaches originate, and you might expect them to point to…
In 2025, 193 innovative drugs received approval in Europe, including 133 new molecular entities (NMEs). Over half – 56% -…
Over the last decade, China has become a key destination for oncology clinical trials, with Chinese sites increasingly incorporated within…
Opinion by Darren Bromley-Davenport, Technical Manager at Orbia Fluor & Energy Materials A tightening regulatory landscape is driving the pharmaceutical…
2026 has brought a plethora of converging technological change and regulatory updates to the life sciences industry at an unprecedented…